Mesoblast and Lonza have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic (off-the-shelf) cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease (aGVHD). This agreement will facilitate inventory build ahead of the planned U.S. market launch of remestemcel-L and commercial supply to meet Mesoblast’s long-term market projections.   Mesoblast expects to complete filing of the rolling Biologics License Appli...